US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Psyence Biomedical Ltd

1.76

-0.0500-2.76%

Post-market: 1.770.0100+0.57%19:50 EST

Volume:61.88K

Turnover:110.86K

Market Cap:3.29M

PE:-0.32

High:1.85

Open:1.81

Low:1.76

Close:1.81

52wk High:62.72

52wk Low:1.41

Shares:1.87M

Float Shares:1.86M

Volume Ratio:0.30

T/O Rate:3.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.5651

EPS(LYR):5.24

ROE:-74.29%

ROA:-34.44%

PB:0.28

PE(LYR):0.34

Loading ...

Overview Company News Filings

US Pharmaceutical Lobbying Group Plans to Launch Website to Help Patients Access Cheaper Medications

PBM Polytex Completes Restoration Work at Petlad, India Unit

MT Newswires Live

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market

Benzinga_recent_news

DBS Hong Kong Completes Pilot Test of 'e-Hong Kong Dollar+' Project Based on Central Bank Digital Currency Technology

Psyence Biomedical Ltd. Announces Completion of Share Purchase Agreement with Psyence Biomed II Corp

PBM Polytex Begins Repair Work at Petlad, India Manufacturing Unit

MT Newswires Live

Psyence Group Inc. Announces Intent to Acquire Goldcoast Resource Corp. in Strategic M&A Move

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

Psyence Biomedical Ltd Files for Offering of up to 8 Mln Shares by Selling Stockholders- SEC Filing

THOMSON REUTERS

Corporate Update, August 2025

Top Premarket Gainers

MT Newswires Live

BRIEF-Psyence Biomedicals’ Strategic Collaboration With Psylabs Yields Breakthrough In High-Purity Ibogaine Production

Psyence Biomed’s Strategic Collaboration With Psylabs Yields Breakthrough in High-Purity Ibogaine Production

THOMSON REUTERS

Psyence Biomedical Ltd. Files Amendment to Annual 10-K Report

Psyence Group Inc. Successfully Closes Second Tranche of Private Placement, Raising Total C$600,000 for Strategic Growth

Psyence Biomedical Reports Surge in Sales and Marketing Costs to $483,530 for FY 2025, Reflects Strategic Focus Post-NASDAQ Listing

Psyence BioMed Chief of Global Impact to Speak at Prestigious Psychedelic Science 2025 Conference

Psyence Biomedical Ltd. Secures Clinical Research Partnership with Southern Star Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PBM/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBM\",,,,,undefined,":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":1.76,"timestamp":1764968400000,"preClose":1.81,"halted":0,"volume":61884,"hourTrading":{"tag":"盘后","latestPrice":1.77,"preClose":1.76,"latestTime":"19:50 EST","volume":6186,"amount":10920.9938,"timestamp":1764982229113},"delay":0,"floatShares":1859800,"shares":1867200,"eps":-5.565065,"marketStatus":"Closed","change":-0.05,"latestTime":"12-05 16:00:00 EST","open":1.81,"high":1.85,"low":1.76,"amount":110857.3638624,"amplitude":0.049724,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.565065,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.81,"preHourTrading":{"tag":"盘前","latestPrice":1.81,"preClose":1.81,"latestTime":"09:29 EST","volume":5374,"amount":9560.0418316,"timestamp":1764944999050},"postHourTrading":{"tag":"盘后","latestPrice":1.77,"preClose":1.76,"latestTime":"19:50 EST","volume":6186,"amount":10920.9938,"timestamp":1764982229113},"volumeRatio":0.297389},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBM\",,,,,undefined,":{"symbol":"PBM","floatShares":1859800,"roa":"-34.44%","roe":"-74.29%","lyrEps":5.241267,"volumeRatio":0.297389,"shares":1867200,"dividePrice":0,"high":1.85,"amplitude":0.049724,"preClose":1.81,"low":1.76,"week52Low":1.41,"pbRate":"0.28","week52High":62.7239,"institutionHeld":0.0125,"latestPrice":1.76,"eps":-5.565065,"divideRate":0,"volume":61884,"delay":0,"ttmEps":-5.565065,"open":1.81,"prevYearClose":16.8167,"prevWeekClose":1.535,"prevMonthClose":1.535,"prevQuarterClose":3.2,"fiveDayClose":1.535,"twentyDayClose":2.513,"sixtyDayClose":3.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-05","symbol":"PBM","defaultRemindTime":1746451800000,"type":"split","dateTimestamp":1746417600000,"forFactor":797,"toFactor":100,"ratio":7.97},{"market":"US","date":"2024-11-26","symbol":"PBM","defaultRemindTime":1732631400000,"type":"split","dateTimestamp":1732597200000,"forFactor":75,"toFactor":1,"ratio":75}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PBM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PBM","date":"2025-12-04","current":-0.323446,"percent":0.26087,"low":-8.987173,"twenty":-1.92814,"median":-0.062237,"eighty":1.579517,"high":43.62106,"avg":0.692829,"sd":6.225812,"marketCap":3332250},"quantilePoints":[{"date":"2024-02-09","current":-4.032357,"twenty":-6.238869,"median":-6.072412,"eighty":-4.789887,"marketCap":12687649},{"date":"2024-02-16","current":-2.839339,"twenty":-6.098548,"median":-3.798256,"eighty":-3.119893,"marketCap":8908805},{"date":"2024-02-23","current":-2.317077,"twenty":-5.416526,"median":-3.308726,"eighty":-2.830575,"marketCap":7275145},{"date":"2024-03-01","current":-2.358335,"twenty":-4.411122,"median":-2.857169,"eighty":-2.443954,"marketCap":7364862},{"date":"2024-03-08","current":-5.40272,"twenty":-4.595223,"median":-2.890292,"eighty":-2.448252,"marketCap":17006136},{"date":"2024-03-15","current":-6.789855,"twenty":-5.670597,"median":-3.448439,"eighty":-2.49853,"marketCap":21291147},{"date":"2024-03-22","current":-4.959176,"twenty":-5.522615,"median":-3.851628,"eighty":-2.531651,"marketCap":15533164},{"date":"2024-03-28","current":-5.045126,"twenty":-5.473209,"median":-4.390178,"eighty":-2.58397,"marketCap":15800977},{"date":"2024-04-05","current":-4.43423,"twenty":-5.384879,"median":-4.562142,"eighty":-2.723572,"marketCap":13926285},{"date":"2024-04-12","current":-3.616183,"twenty":-5.308825,"median":-4.386712,"eighty":-2.826193,"marketCap":11169148},{"date":"2024-04-19","current":-2.969424,"twenty":-5.158983,"median":-4.227564,"eighty":-2.846471,"marketCap":9153854},{"date":"2024-04-26","current":-3.634228,"twenty":-5.044947,"median":-3.989124,"eighty":-2.883667,"marketCap":11244136},{"date":"2024-05-03","current":-5.498334,"twenty":-5.135216,"median":-4.022166,"eighty":-2.931227,"marketCap":17006136},{"date":"2024-05-10","current":-4.755664,"twenty":-5.044947,"median":-4.198236,"eighty":-2.950931,"marketCap":14729724},{"date":"2024-05-17","current":-3.914422,"twenty":-5.029183,"median":-4.161003,"eighty":-2.965515,"marketCap":12185499},{"date":"2024-05-24","current":-3.576034,"twenty":-4.995271,"median":-3.989124,"eighty":-2.992841,"marketCap":11063362},{"date":"2024-05-31","current":-2.410174,"twenty":-4.97525,"median":-3.912167,"eighty":-2.927321,"marketCap":10042674},{"date":"2024-06-07","current":-2.153089,"twenty":-4.945403,"median":-3.739796,"eighty":-2.692286,"marketCap":8971456},{"date":"2024-06-14","current":-1.939708,"twenty":-4.890182,"median":-3.700097,"eighty":-2.466859,"marketCap":8082344},{"date":"2024-06-21","current":-1.253291,"twenty":-4.889663,"median":-3.668675,"eighty":-2.422386,"marketCap":5222190},{"date":"2024-06-28","current":-0.96407,"twenty":-4.844987,"median":-3.634228,"eighty":-2.361971,"marketCap":4017069},{"date":"2024-07-05","current":-0.935148,"twenty":-4.815866,"median":-3.576034,"eighty":-2.32332,"marketCap":3896557},{"date":"2024-07-12","current":-0.998455,"twenty":-4.766248,"median":-3.491099,"eighty":-2.088818,"marketCap":4160345},{"date":"2024-07-19","current":-1.323989,"twenty":-4.726555,"median":-3.448439,"eighty":-1.937394,"marketCap":5516775},{"date":"2024-07-26","current":-1.867403,"twenty":-4.683035,"median":-3.197485,"eighty":-1.910851,"marketCap":7781064},{"date":"2024-08-02","current":-0.143956,"twenty":-4.658595,"median":-2.969424,"eighty":-1.31949,"marketCap":7364628},{"date":"2024-08-09","current":-0.138564,"twenty":-4.597134,"median":-2.93318,"eighty":-1.252648,"marketCap":7088789},{"date":"2024-08-16","current":-0.175224,"twenty":-4.56626,"median":-2.839339,"eighty":-1.14223,"marketCap":8964295},{"date":"2024-08-23","current":-0.164846,"twenty":-4.484876,"median":-2.620747,"eighty":-1.025128,"marketCap":8433350},{"date":"2024-08-30","current":-0.133743,"twenty":-4.446042,"median":-2.530201,"eighty":-0.96664,"marketCap":6842183},{"date":"2024-09-06","current":-0.062172,"twenty":-4.437003,"median":-2.444094,"eighty":-0.946331,"marketCap":3180663},{"date":"2024-09-13","current":-0.050913,"twenty":-4.377208,"median":-2.41628,"eighty":-0.171823,"marketCap":2604637},{"date":"2024-09-20","current":-0.039131,"twenty":-4.329259,"median":-2.362614,"eighty":-0.163756,"marketCap":2001897},{"date":"2024-09-27","current":-0.035312,"twenty":-4.305444,"median":-2.355493,"eighty":-0.148457,"marketCap":1806550},{"date":"2024-10-04","current":-0.032669,"twenty":-4.254131,"median":-2.317077,"eighty":-0.14305,"marketCap":1671309},{"date":"2024-10-11","current":-0.031494,"twenty":-4.19237,"median":-2.120953,"eighty":-0.135288,"marketCap":1611202},{"date":"2024-10-18","current":-0.035247,"twenty":-4.164165,"median":-2.088818,"eighty":-0.127633,"marketCap":1803210},{"date":"2024-10-25","current":-0.031592,"twenty":-4.083815,"median":-1.933924,"eighty":-0.075611,"marketCap":1616211},{"date":"2024-11-01","current":-0.02265,"twenty":-4.026242,"median":-1.927818,"eighty":-0.057485,"marketCap":1158729},{"date":"2024-11-08","current":-0.024869,"twenty":-3.982516,"median":-1.638758,"eighty":-0.044294,"marketCap":1272265},{"date":"2024-11-15","current":-0.049784,"twenty":-3.931086,"median":-1.323989,"eighty":-0.044294,"marketCap":2546883},{"date":"2024-11-22","current":-0.042798,"twenty":-3.911717,"median":-1.256183,"eighty":-0.044338,"marketCap":2189514},{"date":"2024-11-29","current":-0.045389,"twenty":-3.854339,"median":-1.251684,"eighty":-0.044435,"marketCap":2322054},{"date":"2024-12-06","current":-0.046144,"twenty":-3.758505,"median":-1.181949,"eighty":-0.045374,"marketCap":2360678},{"date":"2024-12-13","current":-0.036019,"twenty":-3.736446,"median":-1.098558,"eighty":-0.042081,"marketCap":1842723},{"date":"2024-12-20","current":-0.213027,"twenty":-3.720507,"median":-1.025128,"eighty":-0.041056,"marketCap":10898254},{"date":"2024-12-27","current":-0.195572,"twenty":-3.702521,"median":-0.998455,"eighty":-0.041494,"marketCap":10005291},{"date":"2025-01-03","current":-0.174804,"twenty":-3.696057,"median":-0.967283,"eighty":-0.041676,"marketCap":8942782},{"date":"2025-01-10","current":-0.147112,"twenty":-3.67593,"median":-0.957643,"eighty":-0.042486,"marketCap":7526104},{"date":"2025-01-17","current":-0.1549,"twenty":-3.667341,"median":-0.574087,"eighty":-0.042776,"marketCap":7924545},{"date":"2025-01-24","current":-0.172934,"twenty":-3.665023,"median":-0.208553,"eighty":-0.043408,"marketCap":8057358},{"date":"2025-01-31","current":-0.14918,"twenty":-3.646165,"median":-0.184323,"eighty":-0.044744,"marketCap":6950578},{"date":"2025-02-07","current":-0.129701,"twenty":-3.623401,"median":-0.178377,"eighty":-0.045379,"marketCap":6043019},{"date":"2025-02-14","current":-0.132551,"twenty":-3.592094,"median":-0.174804,"eighty":-0.045783,"marketCap":6175832},{"date":"2025-02-21","current":-0.123525,"twenty":-3.571282,"median":-0.172934,"eighty":-0.046085,"marketCap":5755256},{"date":"2025-02-28","current":-0.117823,"twenty":-3.543472,"median":-0.170272,"eighty":-0.046183,"marketCap":5489629},{"date":"2025-03-07","current":-0.087417,"twenty":-3.495369,"median":-0.16615,"eighty":-0.046596,"marketCap":4072950},{"date":"2025-03-14","current":-0.074485,"twenty":-3.463351,"median":-0.163664,"eighty":-0.047435,"marketCap":3470419},{"date":"2025-03-21","current":-0.059349,"twenty":-3.451625,"median":-0.159632,"eighty":-0.048363,"marketCap":2765179},{"date":"2025-03-28","current":-0.05971,"twenty":-3.386977,"median":-0.158361,"eighty":-0.049116,"marketCap":2782002},{"date":"2025-04-04","current":-0.04489,"twenty":-3.267253,"median":-0.1549,"eighty":-0.049116,"marketCap":2091532},{"date":"2025-04-11","current":-0.043618,"twenty":-3.203179,"median":-0.154152,"eighty":-0.046323,"marketCap":2032227},{"date":"2025-04-17","current":-0.042568,"twenty":-3.140804,"median":-0.151236,"eighty":-0.046065,"marketCap":1983334},{"date":"2025-04-25","current":-0.053422,"twenty":-3.016258,"median":-0.148843,"eighty":-0.045369,"marketCap":2489014},{"date":"2025-05-02","current":-0.04217,"twenty":-2.968121,"median":-0.146958,"eighty":-0.044944,"marketCap":1964773},{"date":"2025-05-09","current":-0.047195,"twenty":-2.958916,"median":-0.143956,"eighty":-0.045202,"marketCap":2198901},{"date":"2025-05-16","current":-0.065096,"twenty":-2.939039,"median":-0.143033,"eighty":-0.045369,"marketCap":3032967},{"date":"2025-05-23","current":-0.055332,"twenty":-2.910166,"median":-0.139192,"eighty":-0.045482,"marketCap":2578022},{"date":"2025-05-30","current":-0.065345,"twenty":-2.857169,"median":-0.138564,"eighty":-0.045852,"marketCap":3044574},{"date":"2025-06-06","current":-0.063844,"twenty":-2.839339,"median":-0.135018,"eighty":-0.046045,"marketCap":2974641},{"date":"2025-06-13","current":-0.058023,"twenty":-2.817429,"median":-0.132806,"eighty":-0.046068,"marketCap":2703424},{"date":"2025-06-20","current":-0.061591,"twenty":-2.692286,"median":-0.131126,"eighty":-0.046129,"marketCap":2869653},{"date":"2025-06-27","current":26.979573,"twenty":-2.596595,"median":-0.130176,"eighty":-0.046129,"marketCap":27297662},{"date":"2025-07-03","current":27.487604,"twenty":-2.551768,"median":-0.129464,"eighty":-0.045667,"marketCap":27811683},{"date":"2025-07-11","current":26.19376,"twenty":-2.531167,"median":-0.127325,"eighty":-0.04489,"marketCap":26502584},{"date":"2025-07-18","current":27.61963,"twenty":-2.482695,"median":-0.125116,"eighty":-0.043883,"marketCap":27945265},{"date":"2025-07-25","current":5.7589,"twenty":-2.446866,"median":-0.121624,"eighty":-0.042776,"marketCap":5826797},{"date":"2025-08-01","current":2.899625,"twenty":-2.443883,"median":-0.117823,"eighty":-0.042564,"marketCap":2933812},{"date":"2025-08-08","current":2.409629,"twenty":-2.430929,"median":-0.116873,"eighty":-0.041187,"marketCap":2438039},{"date":"2025-08-15","current":1.931163,"twenty":-2.415059,"median":-0.115922,"eighty":-0.040303,"marketCap":1953931},{"date":"2025-08-22","current":1.844692,"twenty":-2.395713,"median":-0.095437,"eighty":-0.03915,"marketCap":1866441},{"date":"2025-08-29","current":1.712105,"twenty":-2.371998,"median":-0.086044,"eighty":-0.036019,"marketCap":1732291},{"date":"2025-09-05","current":1.487283,"twenty":-2.362357,"median":-0.084153,"eighty":-0.035684,"marketCap":1504818},{"date":"2025-09-12","current":1.867751,"twenty":-2.360517,"median":-0.075977,"eighty":-0.035051,"marketCap":1889772},{"date":"2025-09-19","current":3.055271,"twenty":-2.356062,"median":-0.074774,"eighty":-0.033798,"marketCap":3091293},{"date":"2025-09-26","current":1.769752,"twenty":-2.341544,"median":-0.069101,"eighty":-0.031722,"marketCap":1790617},{"date":"2025-10-03","current":1.896574,"twenty":-2.321759,"median":-0.068517,"eighty":-0.030678,"marketCap":1918935},{"date":"2025-10-10","current":2.132926,"twenty":-2.285546,"median":-0.066599,"eighty":-0.029539,"marketCap":2158073},{"date":"2025-10-17","current":1.988809,"twenty":-2.204185,"median":-0.065502,"eighty":-0.025065,"marketCap":2012257},{"date":"2025-10-24","current":1.922516,"twenty":-2.127381,"median":-0.065096,"eighty":-0.022271,"marketCap":1945182},{"date":"2025-10-31","current":1.80434,"twenty":-2.088818,"median":-0.063691,"eighty":1.436554,"marketCap":1825613},{"date":"2025-11-07","current":1.448659,"twenty":-2.088818,"median":-0.062888,"eighty":1.555882,"marketCap":1465739},{"date":"2025-11-14","current":1.608341,"twenty":-2.06311,"median":-0.062194,"eighty":1.555882,"marketCap":1627303},{"date":"2025-11-21","current":3.182406,"twenty":-1.990611,"median":-0.061648,"eighty":1.615259,"marketCap":3219927},{"date":"2025-11-28","current":-0.729044,"twenty":-1.937394,"median":-0.062172,"eighty":1.602576,"marketCap":2873598},{"date":"2025-12-04","current":-0.845406,"twenty":-1.92814,"median":-0.062237,"eighty":1.579517,"marketCap":3332250}],"updateTime":1764961322364},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBM\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1191549198","title":"US Pharmaceutical Lobbying Group Plans to Launch Website to Help Patients Access Cheaper Medications","url":"https://stock-news.laohu8.com/highlight/detail?id=1191549198","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191549198?lang=en_us&edition=fundamental","pubTime":"2025-09-29 23:23","pubTimestamp":1759159417,"startTime":"0","endTime":"0","summary":"The Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. pharmaceutical industry's lobbying organization, announced on Monday that it will launch a new website in January next year...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","PBM","01477","BK1574","BK4139"],"gpt_icon":0},{"id":"2568423168","title":"PBM Polytex Completes Restoration Work at Petlad, India Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2568423168","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568423168?lang=en_us&edition=fundamental","pubTime":"2025-09-18 13:32","pubTimestamp":1758173555,"startTime":"0","endTime":"0","summary":"Textile manufacturer PBM Polytex  has completed the restoration and repair work at the Petlad manufacturing unit in Gujarat, India, after a fire incident in August, according to a BSE filing on Thursday.The restoration of the unit was completed within the estimated timelines after the necessary repairs, testing, and safety inspections.The factory has now resumed normal operations and is fully functional, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PBM","MNDmain","BK4139"],"gpt_icon":0},{"id":"2567024581","title":"SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2567024581","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567024581?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:05","pubTimestamp":1758024300,"startTime":"0","endTime":"0","summary":"Arbli is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/16/3150769/0/en/SCIENTURE-Secures-PBM-Led-GPO-Rebate-Agreement-to-Drive-Expanded-Commercial-Coverage-and-Formulary-Access-for-Arbli-losartan-potassium-in-the-256M-U-S-Losartan-Market.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","ARB","BK4139","SCNX","BK4167"],"gpt_icon":0},{"id":"2567102660","title":"EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2567102660","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567102660?lang=en_us&edition=fundamental","pubTime":"2025-09-16 19:45","pubTimestamp":1758023100,"startTime":"0","endTime":"0","summary":"Scienture's Arbli, the first ready-to-use liquid losartan, gains formulary access with coverage for over 100 million lives and discussions for broader access.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/16/Pulmonary-Hypertension-Medicine-Doctor-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/16/Pulmonary-Hypertension-Medicine-Doctor-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/09/47687346/exclusive-scienture-secures-pbm-led-rebate-agreement","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/09/47687346/exclusive-scienture-secures-pbm-led-rebate-agreement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2567812005","title":"DBS Hong Kong Completes Pilot Test of 'e-Hong Kong Dollar+' Project Based on Central Bank Digital Currency Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2567812005","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567812005?lang=en_us&edition=fundamental","pubTime":"2025-09-16 11:23","pubTimestamp":1757992980,"startTime":"0","endTime":"0","summary":"BlockBeats News, September 16th, according to the Hong Kong Economic Times, DBS Hong Kong has announced the completion of the HKMA's e-Hong Kong Dollar CBDC pilot phase 2 testing, exploring how tokenization and programmability can enhance digital fiat applications.This pilot project is supported by DBS Bank's Tokenization Service, integrating tokenization and smart contract technology with the bank's banking transaction services, using Purpose-Bound Money  technology to test adding specific spending conditions to digital currencies such as the e-Hong Kong Dollar. The related applications can be extended to other reward programs, financial management, supply chain payments, and enhanced payment process management.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"theblockbeats_live","url":"https://www.theblockbeats.info//en/flash/312426","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/312426","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["LU2506951875.HKD","LU1497733631.SGD","PBM","DBS","LU0823397103.USD","SG9999014302.SGD","RJAW.SI","SG9999001127.SGD","LU2257852520.SGD","IE0031814969.USD","SG9999006266.SGD","LU0011963245.USD","LU0532188223.SGD","LU0823417737.USD","SGXZ27511609.SGD","IE00BVYPNQ40.USD","LU1282649067.USD","LU0128522157.USD","LU0873338254.USD","LU0061477393.USD","LU0188438112.USD","LU0543330483.HKD","LU0577902538.SGD","LU1504937902.USD","SG9999002620.SGD","LU1770036033.HKD","LU0577902611.USD","BK4139","LU1634259557.SGD","LU0048597586.USD","LU0630378429.USD","SG9999003800.SGD","LU0384037296.USD","LU0488056044.USD","LU0205439572.USD","IE00BVYPNP33.GBP","SG9999005177.SGD","LU1282649810.SGD","SG9999003826.SGD","D05.SI","LU0084288322.USD","LU0823417653.USD","LU0886674414.USD","LU1839390173.USD","LU0955623706.USD","LU0823413587.USD","LU0557290698.USD","LU0235996351.USD","BK6112","LU0326948709.USD"],"gpt_icon":1},{"id":"2565593856","title":"Psyence Biomedical Ltd. Announces Completion of Share Purchase Agreement with Psyence Biomed II Corp","url":"https://stock-news.laohu8.com/highlight/detail?id=2565593856","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565593856?lang=en_us&edition=fundamental","pubTime":"2025-09-06 04:06","pubTimestamp":1757102765,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has announced an agreement with Psyence Labs Ltd. for a transaction involving the issuance and purchase of shares. According to the details disclosed, Psyence Biomed II Corp., a subscriber, will acquire 1,750 subscription shares at a price of US$2000. The transaction aims to further the business activities of Psyence Labs, which includes psychedelic cultivation and extraction based in Southern Africa, along with the export of raw materials to various partners for the development of pharmaceutical-grade psychedelic substances. The agreement was signed on August 15, 2025, in Toronto, with Jody Aufrichtig, Chairman of the Board, representing the subscriber.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Bio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDLXCVmJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2562946789","title":"PBM Polytex Begins Repair Work at Petlad, India Manufacturing Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2562946789","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562946789?lang=en_us&edition=fundamental","pubTime":"2025-08-26 17:08","pubTimestamp":1756199287,"startTime":"0","endTime":"0","summary":"PBM Polytex  has begun the repair and restoration work at its Petlad manufacturing unit in India to rectify the damage caused due to the fire earlier in the month, according to a BSE filing on Tuesday.The restoration and repair work is expected to take an additional seven to 10 days to complete before resumption of production.The company said its operations were covered under comprehensive insurance policies.The company's shares were down over 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNDmain","BK4139","PBM"],"gpt_icon":0},{"id":"2561405403","title":"Psyence Group Inc. Announces Intent to Acquire Goldcoast Resource Corp. in Strategic M&A Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2561405403","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561405403?lang=en_us&edition=fundamental","pubTime":"2025-08-22 23:23","pubTimestamp":1755876238,"startTime":"0","endTime":"0","summary":"Psyence Group Inc. has announced that it has entered into a letter of intent to acquire Goldcoast Resource Corp. The acquisition will involve Psyence acquiring all issued and outstanding securities of GoldCoast, a company known for its environmentally responsible shallow-water mineral exploration off the coast of Ghana. As part of this agreement, Psyence will provide a US$250,000 secured loan to GoldCoast, which will aid in the preparation and submission of an exploration license application and a NI 43-101 Qualified Persons report. The company's common shares are expected to remain halted pending further review and conditions satisfaction. Psyence will provide updates as more material information becomes available.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL48LbHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Psyence Group Inc. Announces Intent to Acquire Goldcoast Resource Corp. in Strategic M&A Move","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2559040546","title":"ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2559040546","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559040546?lang=en_us&edition=fundamental","pubTime":"2025-08-13 19:00","pubTimestamp":1755082800,"startTime":"0","endTime":"0","summary":"$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term gr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/13/3132441/0/en/ARS-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Highlights-Accelerating-Growth-for-neffy-epinephrine-nasal-spray.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PBM","EMA","BK4008","BK4500","ALK","BK4585","BK4081","BK4139"],"gpt_icon":0},{"id":"2557374270","title":"Psyence Biomedical Ltd Files for  Offering of up to 8 Mln Shares by Selling Stockholders- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2557374270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557374270?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:31","pubTimestamp":1754483476,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY0LW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2556381431","title":"Corporate Update, August 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2556381431","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556381431?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:30","pubTimestamp":1754310600,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug.  04, 2025  (GLOBE NEWSWIRE) --  From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop saf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/04/3126547/0/en/Corporate-Update-August-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVA","BK4139","BK4196","BK4559","BK4588","PBM","BK4585"],"gpt_icon":0},{"id":"2556389572","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2556389572","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556389572?lang=en_us&edition=fundamental","pubTime":"2025-08-04 19:58","pubTimestamp":1754308738,"startTime":"0","endTime":"0","summary":"Psyence Biomedical  shares were 87% higher pre-bell Monday, rebounding from Friday's slide.Steelcase  was up 40% after the company agreed to a $2.2 billion takeover by HNI .CommScope  shares were 73% higher after it reported higher Q2 adjusted earnings and revenue and after Amphenol  said it agreed to buy CommScope's CCS business for $10.5 billion in cashGyrodyne  stock was up 41%, adding to Friday's gains.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4233","HNI","GYRO","LU2322448957.HKD","LU2473716301.USD","IE00BQXX3D17.EUR","BK4588","IE00BQXX3F31.USD","LU1992135472.HKD","LU1244550577.SGD","IE00BYQQ9H92.USD","LU2272731782.SGD","SG9999014914.USD","BK4020","IE00B5TLWC47.USD","BK4139","SCS","IE00BQXX3C00.GBP","IE00BFXG0V08.USD","SG9999018857.SGD","SG9999014880.SGD","SG9999014898.SGD","SG9999017495.SGD","IE00BGHQF417.EUR","SG9999014906.USD","COMM","BK4148","IE00B3CCJ633.GBP","APH.AU","IE00BD6J9T35.USD","LU1992135399.USD","LU1244550494.USD","LU2272731600.USD","SG9999018865.SGD","LU1244550221.USD","SGXZ31699556.SGD","APH","BK4512","LU2272731865.HKD","IE00BZ199S13.USD","BK4590","BK4205","BK4585","LU2322448791.USD","PBM","IE00B2PGVK34.USD","LU2048586759.USD","BK4143"],"gpt_icon":0},{"id":"2555985838","title":"BRIEF-Psyence Biomedicals’ Strategic Collaboration With Psylabs Yields Breakthrough In High-Purity Ibogaine Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2555985838","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555985838?lang=en_us&edition=fundamental","pubTime":"2025-07-31 20:15","pubTimestamp":1753964105,"startTime":"0","endTime":"0","summary":"BRIEF-Psyence Biomedicals’ Strategic Collaboration With Psylabs Yields Breakthrough In High-Purity Ibogaine ProductionJuly 31 (Reuters) - Psyence Biomedical Ltd PBM.O:PSYENCE BIOMED’S STRATEGIC COLLAB","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUA5BFNXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2555887855","title":"Psyence Biomed’s Strategic Collaboration With Psylabs Yields Breakthrough in High-Purity Ibogaine Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2555887855","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555887855?lang=en_us&edition=fundamental","pubTime":"2025-07-31 19:30","pubTimestamp":1753961401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUA5BFNXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2554794995","title":"Psyence Biomedical Ltd. Files Amendment to Annual 10-K Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2554794995","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554794995?lang=en_us&edition=fundamental","pubTime":"2025-07-26 04:12","pubTimestamp":1753474360,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has filed an amendment to their 10-K annual report for the fiscal year ended March 31, 2025. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nNDLDlQ1m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2549568349","title":"Psyence Group Inc. Successfully Closes Second Tranche of Private Placement, Raising Total C$600,000 for Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2549568349","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549568349?lang=en_us&edition=fundamental","pubTime":"2025-07-08 05:00","pubTimestamp":1751922028,"startTime":"0","endTime":"0","summary":"Psyence Group Inc.  has successfully closed the second tranche of its non-brokered private placement, raising a total of C$600,000 through the issuance of 6,000,000 common shares at C$0.10 per share. The offering was divided into two tranches: the first tranche closed on June 25, 2025, with 4,760,000 shares issued for C$476,000, and the second tranche closed on July 4, 2025, with 1,240,000 shares issued for C$124,000. The net proceeds will be utilized to support Psyence's ongoing general working capital needs, including operational expenses and strategic growth initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Group Inc. published the original content used to generate this news brief via ACCESS Newswire  on July 07, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nNDLZJpxf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2546226024","title":"Psyence Biomedical Reports Surge in Sales and Marketing Costs to $483,530 for FY 2025, Reflects Strategic Focus Post-NASDAQ Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2546226024","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546226024?lang=en_us&edition=fundamental","pubTime":"2025-06-26 05:18","pubTimestamp":1750886296,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Reports Surge in Sales and Marketing Costs to $483,530 for FY 2025, Reflects Strategic Focus Post-NASDAQ Listing. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL3mDX6g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Psyence Biomedical Reports Surge in Sales and Marketing Costs to $483,530 for FY 2025, Reflects Strategic Focus Post-NASDAQ Listing","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM"],"gpt_icon":0},{"id":"2546038223","title":"Psyence BioMed Chief of Global Impact to Speak at Prestigious Psychedelic Science 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2546038223","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546038223?lang=en_us&edition=fundamental","pubTime":"2025-06-26 04:01","pubTimestamp":1750881709,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. is set to participate in Psychedelic Science 2025, the world's largest international gathering focused on psychedelic research, taking place from June 16-20, 2025, in Denver, Colorado. At the event, Psyence BioMed will present on business ethics in a panel session titled \"We are the Guardrails: Profit with Purpose,\" focusing on the intersection of patient care and shareholder value.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 25, 2025, and is solely responsible for the information conta","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL5btms6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2542320985","title":"Psyence Biomedical Ltd. Secures Clinical Research Partnership with Southern Star Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2542320985","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542320985?lang=en_us&edition=fundamental","pubTime":"2025-06-12 04:07","pubTimestamp":1749672451,"startTime":"0","endTime":"0","summary":"Psyence Biomedical Ltd. has entered into a significant Master Services Agreement with Southern Star Research Pty Ltd, a renowned provider of contract clinical research services. Under this agreement, signed on May 21, 2025, Southern Star Research will provide clinical research services to support Psyence's business operations in Australia. As part of the agreement, Psyence will act as the local study sponsor for any projects, ensuring adequate clinical trials liability insurance is in place to meet local regulatory requirements. This collaboration aims to advance Psyence's clinical projects effectively and efficiently, leveraging Southern Star's expertise in clinical research.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biom","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDLF7xFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","LU1923622291.USD","LU1481599808.USD","LU2125909916.SGD","LU1196032939.SGD","LU1487256676.USD","BK5061","RTO.UK","BK4139","LU2125909759.SGD","LU1273509221.SGD","LU1481600234.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":39,"code":"91000000","status":"200"}]}}